Cipla Stock

Cipla EBIT per Employee

The EBIT per Employee of Cipla (CIPLA.NS) as of Aug 5, 2026 is 2.81 M INR. In the previous year, EBIT per Employee was 2.45 M INR — a change of 14.62% (higher).

EBIT per Employee

2.81 MINR

YoY

14.62%

Last updated:

EBIT per Employee of Cipla is 2026 2.81 M INR. EBIT per Employee of Cipla was 2025 2.45 M INR. It decreases by 14.62% higher compared to the previous year.
Access this data via the Eulerpool API

Cipla Stock analysis

What does Cipla do? Cipla Ltd is an Indian pharmaceutical company based in Mumbai. The company was founded in 1935 and is now one of the largest producers of generics worldwide. The name "Cipla" is an abbreviation for "Chemical, Industrial & Pharmaceutical Laboratories". Business Model: Cipla specializes in the production of high-quality generics. This means that they manufacture medication that has the same active ingredients as the original drugs. This allows them to offer medication at a significantly lower price. However, Cipla not only offers generics but also develops its own innovative medication. The focus is on therapy areas such as oncology, respiratory diseases, HIV/AIDS, diabetes, and cardiovascular diseases. Divisions: Cipla is divided into several divisions, including generics, specialty drugs, and biologics. The generics division is the company's core competence. Here, Cipla produces a variety of medications in different forms, such as tablets, capsules, suspensions, etc. The specialty drugs division focuses on innovative medications that are usually more expensive than generics. This includes medications for the treatment of cancer or autoimmune diseases. In the biologics division, Cipla produces biotechnology products based on the use of living cells. Products: Cipla offers a wide range of products, including medications for asthma, diabetes, hypertension, and infectious diseases. Some of the most well-known medications are Escitalopram (an antidepressant), Seroflo (an asthma medication), Tenofovir (an HIV medication), and Sorafenib (a cancer medication). The company continuously works on new products and invests heavily in research and development. Cipla also has a social responsibility. The company is involved in the fight against HIV/AIDS and produces life-saving medication for this disease at an affordable price. Furthermore, Cipla has launched a program called "Cipla Foundation" which works towards improving healthcare in developing countries. Overall, Cipla has achieved impressive growth and is now one of the most significant pharmaceutical companies worldwide. The company has proven that it is possible to offer high-quality medication at an affordable price and still be successful. Cipla is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cipla stock

EBIT per Employee of Cipla is 2.81 M INR in 2026.

EBIT per Employee of Cipla changed from 2.45 M INR to 2.81 M INR, representing a 14.62% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Employee Cipla since 2006 – with annual values, charts, and detailed analysis.

EBIT per employee measures operating profit per employee, showing how efficiently the workforce generates operating earnings.

EBIT per Employee's INR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT per Employee's Cipla historically and in real time.

Access this data via the Eulerpool API

Workforce — Cipla

All Key Metrics — Cipla